Last reviewed · How we verify

NCT06242145

Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke

Completed Phase 3 Last updated 20 August 2024
What this trial tests

Phase 3 trial testing Clopidogrel tablet in Ischemic Stroke in 580 participants. Completed in 1 August 2024.

Timeline
1 January 2023
Primary endpoint
1 July 2024
1 August 2024

Quick facts

Lead sponsorKafrelsheikh University
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment580
Start date1 January 2023
Primary completion1 July 2024
Estimated completion1 August 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Kafrelsheikh University

Who can join

Adults 18 to 75, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Cilostazole versus clopidogrel in acute large-vessel moderate and moderate-to-severe ischemic stroke: a randomized controlled trial.
    Ahmed SR, Khalil MFE, Ismaiel M, Omar TY, et al · · 2025 · cited 1× · PMID 40232632 · DOI 10.1007/s10072-025-08107-9

Verify or expand the search:

Other trials of Clopidogrel tablet

Trials testing the same drug.

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

Other Kafrelsheikh University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06242145.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing